Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN7 | P35236 | 3/20 | 0.37 |
| ▸ | DUSP3 | P51452 | 3/20 | 0.37 |
| ▸ | KIF11 | P52732 | 3/20 | 0.35 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | F2R | P25116 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19841847 | 0.82 | F2R (0.31) | KIF11P2RX7F2R | |
| SCHEMBL26420508 | 0.79 | ALDH1A1 (0.44) | KIF11GAAPOLB | |
| SCHEMBL22761783 | 0.77 | HTR2A (0.39) | PTPN7DUSP3POLB | |
| SCHEMBL24065732 | 0.76 | HSD11B1 (0.36) | SLC22A12TRPV1NR3C1 | |
| SCHEMBL24065730 | 0.76 | PDE2A (0.32) | — | |
| SCHEMBL25733977 | 0.75 | GAA (0.34) | PYCR1GAAPOLB | |
| SCHEMBL21677385 | 0.75 | GABRA1 (0.35) | KIF11NR3C1 | |
| SCHEMBL24610558 | 0.74 | PYCR1 (0.36) | SLC22A12ARPYCR1NR3C1 | |
| SCHEMBL19185444 | 0.72 | KIF11 (0.34) | PTPN7DUSP3KIF11NR3C1 | |
| SCHEMBL22649210 | 0.71 | PLA2G1B (0.33) | NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10723738-B2 | Inhibitors of KRAS G12C mutant proteins | ARAXES PHARMA LLC (US) | 2020-07-28 | — | — | US | disclosed |
| US-20200062761-A1 | INHIBITORS OF KRAS G12C MUTANT PROTEINS | ARAXES PHARMA LLC | 2020-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10723738-B2 | Inhibitors of KRAS G12C mutant proteins | KRAS, NRAS, HRAS | PTPN7 962/4885DUSP3 564/4885KIF11 1894/4885 |
| US-20200062761-A1 | INHIBITORS OF KRAS G12C MUTANT PROTEINS | KRAS, NRAS, HRAS | PTPN7 962/4885DUSP3 564/4885KIF11 1894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.